Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Vericel Corp director Lisa Wright reported equity compensation and a deferral election, with no open-market buying or selling. She exercised 3,200 Restricted Stock Units (RSUs) into an equal number of Phantom Stock units under Vericel’s Deferred Compensation Plan, and holds 15,851 shares of common stock afterward.
Wright also received a new grant of 3,200 RSUs, each representing one share of common stock, which vest 100% on the earlier of April 30, 2026, or the first Annual Meeting of Stockholders after April 30, 2025. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43, vesting in equal monthly increments over one year and expiring on April 29, 2036.
Vericel Corp director Robert L. Zerbe, M.D. reported equity compensation activity with no open-market buying or selling. On April 29, 2026, 3,200 Restricted Stock Units (RSUs) vested and were exercised into 3,200 shares of Vericel common stock, bringing his direct common stock holdings to 32,995 shares.
On the same date, he received new equity awards: a grant of 3,200 RSUs, each representing a contingent right to one share of common stock, that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026, and a grant of stock options for 8,000 shares of common stock at an exercise price of $33.43 per share, vesting monthly over one year and expiring on April 29, 2036.
Vericel Corporation reported the results of its annual shareholder meeting held on April 29, 2026. Shareholders elected seven directors — Robert Zerbe, Alan Rubino, Heidi Hagen, Kevin McLaughlin, Paul Wotton, Lisa Wright and Dominick Colangelo — each to one-year terms. Votes "for" each director ranged from 38,296,679 to 45,198,344, with broker non-votes of 2,162,887 on each nominee. Shareholders also approved, on a non-binding advisory basis, the compensation of Vericel's named executive officers, with 36,350,150 votes for, 9,725,057 against and 30,539 abstentions, plus 2,162,887 broker non-votes. In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, by 44,971,340 votes for, 3,275,442 against and 21,851 abstentions.
Vericel Corp reports institutional ownership disclosure by Vanguard Capital Management. Vanguard Capital Management states it beneficially owns 2,603,128 shares of Common Stock, representing 5.11% of the class. The filing shows sole voting power for 372,372 shares and sole dispositive power for 2,603,128 shares, with holdings held on behalf of various Vanguard affiliates and client accounts.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper exercised and sold a small block of shares in a pre-planned transaction. On April 2, 2026 he exercised stock options for 3,472 shares of common stock at $10.95 per share and sold the same 3,472 shares at $35.00 per share under an automatic Rule 10b5-1 trading plan. After these transactions, he directly holds 75,556 Vericel common shares and 9,132 stock options that are exercisable at $10.95 per share and expire on August 20, 2028.
Vericel Corp reports that Soleus Capital Master Fund, L.P. and affiliated entities hold 2,549,079 shares of common stock. The filing states this equals 5.0% of Vericel's outstanding common shares, based on 50,763,319 shares outstanding as of February 19, 2026. The ownership is reported as shared voting and dispositive power among the fund and affiliated entities, with Guy Levy identified as the managing member signing the joint filing agreement.
Vericel Corp director Alan L. Rubino exercised stock options to acquire 15,000 shares of common stock at $2.76 per share and chose to hold all of these shares. These options were originally granted on May 4, 2016 and would otherwise have expired on May 4, 2026. Following the exercise, Rubino directly owns 60,994 shares of Vericel common stock, and the exercised option grant has been fully used with no remaining derivative position from this award.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting zero beneficial ownership of Vericel Corp common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own those securities.
The filing lists Amount beneficially owned: 0 and Percent of class: 0%, and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Vericel director Heidi Hagen exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.76 per share, then sold the same 15,000 shares at $32.41 per share on March 23, 2026.
The sale was carried out automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2024. These options were originally granted on May 4, 2016 and would have expired on May 4, 2026 if not exercised. Following the transactions, Hagen holds 31,850 shares of Vericel common stock directly.